The leaders of this startup, backed with $800 million and a facility in Fremont, believe they can spearhead manufacturing changes that will deliver cutting-edge cell, gene and RNA-based therapies faster and cheaper, making those more accessible to more patients.
Click here to read the original article in San Francisco Business Times.